{"id":1020286,"date":"2026-11-12T09:30:00","date_gmt":"2026-11-12T14:30:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-third-quarter-2026-financial-results-and-business-update\/"},"modified":"2026-11-12T09:30:00","modified_gmt":"2026-11-12T14:30:00","slug":"altimmune-announces-third-quarter-2026-financial-results-and-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-third-quarter-2026-financial-results-and-business-update\/","title":{"rendered":"Altimmune Announces Third Quarter 2026 Financial Results and Business Update"},"content":{"rendered":"
\n

\n Global PERFORMA Phase 3 trial in MASH progressing as planned<\/em>\n <\/p>\n

\n Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation <\/em>
\n
\n at AASLD The Liver Meeting\u00ae 2026<\/em>\n <\/p>\n

\n End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026<\/em>\n <\/p>\n

\n $480 million in cash, cash equivalents and investments as of September 30, 2026<\/em>\n <\/p>\n

\n Webcast to be held today at 8:30 a.m. ET<\/em>\n <\/p>\n

MORRISTOWN, N.J., Nov. 12, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc.<\/a> (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon\/GLP-1 dual receptor agonist, in serious liver diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.<\/p>\n

\u201cWe continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide\u201d said Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune. \u201cOur global PERFORMA Phase 3 trial in MASH is ramping up, and we are very encouraged by the progress to date and the enthusiasm we see from the MASH community. In AUD, we look forward to engaging with the FDA in an End-of-Phase 2 meeting where we will leverage our strong RECLAIM data to discuss a Phase 3 registrational program. Following the recent AASLD meeting, our conviction in pemvidutide\u2019s potential is stronger than ever, as we focus on delivering meaningful benefit to patients with serious liver diseases.\u201d<\/p>\n

\n
\n Key Highlights and Anticipated Milestones<\/u>
\n <\/strong>\n <\/p>\n

\n Metabolic Dysfunction-Associated Steatohepatitis<\/strong>
\n (MASH)<\/strong>\n <\/p>\n